Magazine
As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”
Magazine
In response to the coronavirus pandemic, Christian Angermayer—the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.
Magazine
The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.
Magazine
After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.
Magazine
Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?
Magazine
Shlomi Raz, CEO of Eleusis Benefit Corporation, made false claims about psychedelics. We asked multiple ethnobotanists, a medical anthropologist, and a chemist if they could help us set the record straight.
Magazine
Could a liquid-delivery system meant to help maintain a personalized “scent bubble” quietly usher in the creation of wearable psychedelic microdosing technology? A U.S. patent for this system is just one among an increasing list of psychedelic-inspired intellectual properties.
Magazine
With the recent creation of the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine in Baltimore, Maryland, we must remember that, while industrialized medicine has never attempted to serve all people, institutional histories vary from one organization to the next.
Magazine
The Multidisciplinary Association for Psychedelic Studies (MAPS) submitted their MDMA PTSD expanded access protocol to the FDA on January 14, 2019.
Magazine
Until MDMA-assisted psychotherapy is proven without a doubt to reduce long-term costs, many insurance companies do not have an incentive to cover it.
Magazine
What does MDMA rescheduling mean for the recreational user? If you are under the impression that MDMA is on its way to being rescheduled, across the board, you may be disappointed.
Magazine
What does the future hold for MDMA? We explore MAPS’ ongoing FDA phase 3 clinical trials, rescheduling, health insurance, and expanded access.